Novartis International AG

Research on hematopoietic reported by M. Xaymardan et al.(Report)
Blood Weekly; 11/19/2009; 882 words; ...inhibitor, Gleevec (imatinib mesylate; Novartis International, Basel, Switzerland, http://www.novartis.com), to the culture. Cluster formation...Imatinib, Imatinib Mesylate, Kinase, Novartis AG, Pharmaceutical Business, Pharmaceutical...

Researchers from Novartis describe findings in pharmacokinetics.(Clinical report)
Biotech Week; 11/18/2009; 902 words; ...avosentan in man. International Journal of Clinical...contact T. Hengelage, Novartis Pharma AG, Clinic Development...information for the International Journal of Clinical...Pharmacology, Drugs, Novartis AG, Pharmaceutical Business...

Biopharma Capitalizes on Global Talent.
Biotech Week; 11/11/2009; 1134 words; ...second year, the Novartis Institute for Biological...regional, and international BioCamps. During the three-day international BioCamp program...Boston biotech hub at Novartis' Cambridge, MA...Drugs, Novartis AG, Patents, Pharmaceutical...

Publication No. WO/2009/132921 Published on Nov. 5, Assigned to Novartis for Spiro-Indole Derivative (Singaporean, Swiss Inventors)
US Fed News Service, Including US State News; 11/9/2009; 427 words; ...parasitic diseases. The patent has been assigned to Novartis AG, Basel, Switzerland. According to an abstract posted...processes for their preparation." The invention carries International Patent Publication No. WO/2009/132921 on Nov...

Publication No. WO/2009/133101 Published on Nov. 5, Assigned to Novartis for Fibroblast Growth Factor Receptor Kinase Activity Modulation Monitoring Method, Usage (Swiss, British Inventors)
US Fed News Service, Including US State News; 11/9/2009; 449 words; ...uses of said methods. The patent has been assigned to Novartis AG, Basel, Switzerland. According to an abstract posted...kits relating to these uses." The invention carries International Patent Publication No. WO/2009/133101 on Nov...